Morgan Stanley rates Cipla overweight post AGM

MUMBAI: Morgan Stanley has rated Cipla an overweight after attending the company's annual general meeting.

""Management commentary suggested that there are three more sizable product opportunities for US after Lexapro (DF supplier to Teva during 180 days exclusivity),"" said Morgan Stanley analysts Sameer Baisiwala and Saniel Chandrawat in a note to clients.

On Friday, Cipla shares fell 0.3% to end at Rs 354.85.

""For FY13, management targets topline growth of 12-15%. Overall, it believes that international business will grow faster than domestic business in the ensuing years. It plans to focus on building the US business and investing in manufacturing assets in emerging markets,"" the analysts said.